KNSA Kiniksa Pharmaceuticals PE ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: KNSA
- PE Ratio
The current price-to-earnings ratio of KNSA can't be determined, as the TTM EPS of -$0.24 is negative. The most recent PE ratio recorded for Kiniksa Pharmaceuticals was 164.42 in March 2024.
KNSA PE ratio history
Over the last three years, the average PE ratio of Kiniksa Pharmaceuticals has been 45.35. In the past three years, KNSA's PE ratio was at its highest in the Mar 2024 quarter at 164.42, with a price of $19.73 and an EPS of $0.12. The Mar 2023 quarter recorded the bottom point at 3.82, with a price of $10.76 and an EPS of $2.82.
Kiniksa Pharmaceuticals PE ratio by year
Maximum annual increase: 1,446.74% in 2023
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2024 | N/A | N/A | $19.78 | -$0.6 |
| 2023 | 87.7 | 1,446.74% | $17.54 | $0.2 |
| 2022 | 5.67 | N/A | $14.98 | $2.64 |
| 2021 | N/A | N/A | $11.77 | -$2.3 |
| 2020 | N/A | N/A | $17.67 | -$2.61 |
| 2019 | N/A | N/A | $11.06 | -$2.99 |
| 2018 | N/A | N/A | $28.09 | -$3.49 |
| 2017 | N/A | N/A | N/A | -$35.85 |
| 2016 | N/A | N/A | N/A | -$91.61 |
Kiniksa Pharmaceuticals PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Mar 2025 | N/A | N/A | $22.21 | -$0.24 |
| Dec 2024 | N/A | N/A | $19.78 | -$0.6 |
| Sep 2024 | N/A | N/A | $24.99 | -$0.13 |
| Jun 2024 | N/A | N/A | $18.67 | -$0.15 |
| Mar 2024 | 164.42 | 87.48% | $19.73 | $0.12 |
| Dec 2023 | 87.7 | N/A | $17.54 | $0.2 |
| Sep 2023 | N/A | N/A | $17.37 | -$0.11 |
| Jun 2023 | 4.24 | 10.99% | $14.08 | $3.32 |
| Mar 2023 | 3.82 | -32.63% | $10.76 | $2.82 |
| Dec 2022 | 5.67 | -8.99% | $14.98 | $2.64 |
| Sep 2022 | 6.23 | N/A | $12.84 | $2.06 |
| Jun 2022 | N/A | N/A | $9.69 | -$1.61 |
| Mar 2022 | N/A | N/A | $9.94 | -$1.93 |
| Dec 2021 | N/A | N/A | $11.77 | -$2.3 |
| Sep 2021 | N/A | N/A | $11.39 | -$2.58 |
KNSA average PE ratio chart
KNSA PE vs peers
| Stock name | PE ratio | Market cap |
|---|---|---|
| OLMA Olema Pharmaceuticals Inc | N/A | $319.8M |
| OMER Omeros Corp | N/A | $368.13M |
| VIVS VivoSim Labs Inc. | N/A | $2.89M |
| ORIC Oric Pharmaceuticals Inc | N/A | $366.81M |
| ORMP Oramed Pharmaceuticals Inc | N/A | $93.55M |
| KNSA Kiniksa Pharmaceuticals Ltd | N/A | $1.93B |
Frequently asked questions
What is Kiniksa Pharmaceuticals's PE ratio?
The current price to earnings ratio of KNSA can't be calculated, as its EPS of -$0.24 is negative.
What is the 3-year average PE ratio for Kiniksa Pharmaceuticals (KNSA)?
Over the last 3 years, the average price to earnings ratio for KNSA stock is 45.35.
What is the 5-year average PE ratio for Kiniksa Pharmaceuticals (KNSA)?
Over the last 5 years, the average price to earnings ratio for KNSA stock is 45.35.
What is the highest PE ratio for KNSA?
Over the last three years, the quarterly PE ratio reached a historic high of 164.42 in the Mar 2024 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.